Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation

Fig. 1

Clinical relevance of MDSCs during induction chemotherapy and ASCT. Serial changes in MDSC phenotypes through induction chemotherapy and ASCT (a). The data are presented as the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. The 100 patients were grouped (low versus high) according to median frequency value of each E- (0.21 for pre-ASCT, 0.85 for post-ASCT) and M-MDSC phenotype (0.15 for pre-ASCT, 1.04 for post-ASCT). The 3-year time to progression (TTP) between the low and high pre-ASCT E-MDSC groups (b, top left) and M-MDSC groups (b, top right). The 3-year TTP according to post-ASCT MDSC phenotype groups are shown at the bottom

Back to article page